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Summary Drug resistance is one of the problems severely limiting chemotherapy in cancer patients. Thus, it is very important to develop
new drugs that are effective against drug-resistant tumour cells. The novel anti-tumour agent NK109 has been developed from
benzo[c]phenanthridine derivatives by Nippon Kayaku (Tokyo, Japan). We have confirmed that NK109 shows anti-tumour effects against a
number of human tumour cell lines by inhibiting DNA topoisomerase 11 activity through the stabilization of the cleavable complex. Further, its
efficacy against several drug-resistant tumour cell lines was also shown. NK109 showed potent anti-tumour activity against doxorubicin-
resistant human tumour cell lines that have a typical multidrug resistance phenotype caused by P-glycoprotein. NK109 was not pumped
extracellularly by P-glycoprotein and, consequently, NK109 accumulated in resistant cells. Cisplatin-resistant human tumour cell lines, which
demonstrated decreased cisplatin accumulation, were sensitive to NK109. NK109 non-cross-resistance was confirmed using xenografts of
tumour cells that were resistant to cisplatin in SCID mice. Furthermore, etoposide-resistant cells, with decreased topoisomerase 11 activity,
were markedly sensitive to NK109 when compared with their parent cells, suggesting the possibility that the cytotoxic mechanism of NK109
differs from that of etoposide. In conclusion, NK109 is a very promising new anti-tumour drug for clinical use, because the efficacy of NK109
is not susceptible to several known molecular alterations that are associated with drug resistance. A clinical study of this compound is now in
progress in Japan.
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There are two strategies for the development of new anti-tumour
drugs. The first is to search for agents that exert cytotoxicity by
aiming at new cellular targets, such as DNA topoisomerase I (topo
I), topo II and protein kinase C (Kanzawa et al, 1990; Kanzawa et
al, 1995; Yoshida et al, 1996). A second is to screen new agents for
their effectiveness against drug-resistant tumour cells (Kanzawa et
al, 1981; Kanzawa et al, 1982; Horichi et al, 1990; Ohmori et al,
1993), because cell resistance to anti-tumour agents severely
limits the chemotherapeutic treatment ofcancerpatients with cyto-
toxic drugs.
Among the many DNA topoisomerase inhibitors examined,
several alkaloids of the benzo[c]phenanthridine family, such as
fagaronine and nitidine (Larsen et al, 1993; Wang, 1993), have
been found to possess antileukaemic activity against several
murine leukaemia cell lines (Barret and Sauvaire, 1992). However,
the clinical application ofthese compounds has not been attempted
because of their low potency in solid tumour models and their
incompatibility with biological fluids.
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A novel synthetic derivative of this family, 2,3-(methylene-
dioxy)-5-methyl-7-hydroxy-8-methoxy-benzo[c]phenanthri-
dinium, called NK109, synthesized by Suzuki and colleagues, has
been shown by Kabasawa et al (1996) to act strongly against
several murine cell lines including P388, L1210 leukaemia, colon
26 and B16 melanoma as well as against a panel ofhuman tumour
cell lines. Its chemical structure is shown in Figure 1. The efficacy
of NKl09 against human tumour xenografts, including lung,
stomach, colon and ovarian carcinomas, demonstrates superiority
to etoposide and similarity to doxorubicin or cisplatin. In cell-free
systems, NK109 inhibits topo II activity through the stabilization
ofthe cleavable complex. NK109 increases the amount ofcellular
DNA-protein complex and induces DNA strand breaks more
intensely than either the other benzophenanthridine alkaloids or
the topo II inhibitor, etoposide (Kabasawa et al, 1996).
OH
Figure 1 Chemical structure of NK109
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In this study, NK109 was found to be active against cisplatin-,
doxorubicin- and etoposide-resistant tumour cells. From these
results, we believe that NK109 will be useful for the treatment of
refractory solid tumours.
MATERIALS AND METHODS
Anti-tumour drugs and materials
2,3-(Methylenedioxy)-5-methyl-7-hydroxy-8-methoxy-benzo-
[c]phenanthridinium hydrogensulphate dihydrate (NK109) and its
tritium-labelled form were obtained from Nippon Kayaku (Tokyo,
Japan). Cisplatin and etoposide were provided by Bristol Myers
Japan (Tokyo, Japan), and doxorubicin was purchased from Kyowa
Hakko Kogyo (Tokyo, Japan). Supercoiled Escherichia coliplasmid
pBR322 DNA and kinetoplast DNA (kDNA) were purchased from
Takara Shuzo (Kyoto, Japan) and purified DNA Topo II was
obtained from TopoGEN (Columbus, OH, USA). Tritium-labelled
azidopine was purchased from Moravek Biochemicals (Brea, CA,
USA). RPMI-1640 medium (Gibco-BRL) and fetal bovine serum
(FBS) were purchased from Nissui (Tokyo, Japan).
Cell lines and culture
The cell lines used were the human cancer cell lines, H69, SBC-3
(small-cell lung cancer), PC-9, PC-14 (non-small-cell lung
cancer), MCF7 (breast cancer), SKOV3 (ovarian carcinoma),
K562 (leukaemia cells) and their drug-resistant sublines. H69 and
SBC-3 were obtained from the National Cancer Institute,
Bethesda, MD, USA, and the Japanese Cancer Research
Resources Bank (Tokyo, Japan) respectively. PC-9 and PC-14
were from Professor Y Hayata (Tokyo Medical College, Tokyo,
Japan). MCF7 and SKOV3 were kindly donated by Dr KH Cowan
(National Cancer Institute, Bethesda, MD, USA) and Dr S Niimi
(Jikei University, Tokyo, Japan) respectively.
The etoposide-resistant cell lines H69/VP (Minato et al, 1990)
and SKOV3/VP (Kubota et al, 1994) and the cisplatin-resistant
PC-9/CDDP and PC-14/CDDP (Hong et al, 1988) were estab-
lished in our laboratory by continuous exposure of cells to step-
wise increasing concentrations ofdrugs, followed by isolation and
growth of resistant clones. The doxorubicin-resistant cell lines
K562/ADM (Tsuruo et al, 1986), AdrR MCF7 (Cowan et al, 1986)
and SBC-3/ADM (Kimura et al, 1987) were donated by Dr T
Tsuruo (TokyoUniversity, Tokyo, Japan), Dr KH Cowan (National
Cancer Institute) and Dr T Ohnoshi (Okayama University,
Okayama, Japan) respectively. AdrR MCF7, SBC-3/ADM and
H69/VP over-express P-glycoprotein (P-gp) and are considered to
have typical P-gp-mediated multidrug resistance (MDR) pheno-
types. SKOV3NP is considered to be an 'atypical MDR' cell line.
The cells were routinely maintained in RPMI-1640 medium
supplemented with 10% heat-inactivated FBS, streptomycin
(100gg ml-') and penicillin (100 IU ml-') in an incubator under a
humidified atmosphere of5% carbon dioxide and95% airat370C, as
described previously (Kanzawa et al, 1990). The cells were subcul-
tured every week in the exponential growth phase. The stability of
thedrug-resistantphenotypes wasconfirmedbyassessing the growth
curves ofcells in the presence ofthe drug concerned.
In vitro cytotoxic effect assay test
The cytotoxic effect was estimated using the regrowth assay
described previously (Kanzawa et al, 1995). Duplicate 10-ml
culture flasks, initially containing 2.5 x 104 cells per ml of
medium and the required drugs at various concentrations, were
incubated for 7 days at 37°C in the incubator, after which the cells
were counted using a TOA Microcellcounter CC-108 (TOA
Medical Electronics, Kobe, Japan) and the cell proliferation ratios
of treated vs control cultures were calculated. Drug antiprolifera-
tive activities were expressed as IC50values, which are the concen-
trations required to inhibit cell proliferation by 50% compared
with control cultures.
Preparation of nuclear extracts
Crude nuclear extracts were prepared as reported previously by
Deffie et al (1989). Cells were collected by centrifugation and
washed twice with ice-cold 2 mM dipotassium hydrogenphosphate,
5 mm magnesium chloride, 150 mm sodium chloride, 1 mM EGTA,
0.1 mM dithiothreitol, pH 6.5 (nucleus buffer, NB). The cells were
resuspended in 1 ml of cold NB, and 9 ml of cold NB containing
0.35% Triton X-100 and 1 mM polymethyl sulphonyl fluoride was
added. The cell suspension was put on ice for 10 min and washed
with Triton X-100 free cold NB. Nuclear protein was eluted for 1 h
at4°C with cold NB containing 0.35 M sodium chloride. A solution
of nuclear protein was obtained by centrifugation at 18 000 g for
10 min. Protein concentration was determined by the method of
Bradford with bovine plasma y-globulin as the standard.
DNA topo I and 11 catalytic activity
Topo I activity was determined bymeasuring therelaxation ofsuper-
coiled pBR322 DNA, as described by Liu and Miller (1981). The
reaction mixtures comprised 100mM potassium chloride,
1Omm magnesium chloride, 1 mm dithiothreitol, 0.1 mM EDTA,
10% glycerol, 50mM Tris-HCl (pH 7.4) and 0.7 jg of pBR322
DNA. The reaction was initiated by the addition of crude nuclear
extracts (0.0003-1.0 jig ml-') and allowed to proceed at 370C for
20 min. Reactions were terminated by adding 5gl of dye solution
containing 1% sodium dodecylsulphate (SDS), 0.05% bromophenol
blue and 10% sucrose. These samples were applied to 0.7% agarose
gels, electrophoresed for4.5 hwith aTris-acetaterunning bufferwith
EDTA, after which the gel was stained with 2jM ethidium bromide
and photographed undertransillumination with 300 nm UV light.
Topo II catalytic activity was assayed by two different methods:
(1) relaxation ofsupercoiled pBR322 DNA to relaxed forms and (2)
decatenation of kDNA into free mini-circles. The former was
performed to examine the inhibiting effect ofNK109 on the Topo II
catalytic activity. The reaction mixtures comprised 100 mm potas-
sium chloride, 10 mm magnesium chloride, 5 mM dithiothreitol,
0.5 mM EDTA, 10% glycerol, 50 mm Tris-HCl (pH 7.4), bovine
serum albumin 10 jg ml' and 1 mim adenosine 5'-triphosphate
(pH 7.7). The reactions were started by addition of purified DNA
Topo II in the presence of supercoiled pBR322 DNA (1.0jg) and
NK109 (0.05-100 jg ml-'), allowed to proceed at 30°C for 15 min
and the reactions were terminated by adding 5 jl of dye solution.
These samples were applied to 1.0% agarose gels, electrophoresed
for 3 h with a Tris-acetate running buffer with EDTA, after which
the gels were stained and photographed (Marini, 1980).
Decatination of kDNA was used to determine the Topo II
catalytic activity of crude nuclear extracts of tumour cells using
kDNA as a substrate. Reaction conditions were as described above
except that 1.0 jg of kDNA was used as substrate instead of
pBR322 DNA. The reaction was initiated by the addition ofcrude
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Figure 2 Inhibitory effect of NK109 on catalytic DNA relaxation by purified yeast DNA Topo II. The enzyme activity was determined by the relaxation of
supercoiled DNA (pBR322 DNA) as described in Materials and methods. Reaction mixtures (20 ,l each) containing NK109 or etoposide at concentrations of
0.05-100 ,ug ml-' were incubated at 370C for 30 min. The electrophoresis was performed on 1.0% agarose gel for 3 h
nuclear extracts (0.001-1.0,g ml-') and incubated at 30°C for
15 min. The subsequent process was carried out as described
above.
Cleavage of DNA by Topo 11
All DNA cleavage reactions used Topo 11(10 jig ml-') and nega-
tively supercoiled pBR322 DNA (50 jig ml-') in a total volume of
20gl ofcleavage buffer (10 mm Tris-HCl, pH 7.9, 50 mm sodium
chloride, 50 mm potassium chloride, 0.1 mM EDTA and 2.5%
glycerol) that contained 5 mm magnesium chloride. Samples were
incubated for 6 min at 30°C. Cleavage products were trapped (Liu
et al, 1983) by the addition of 2 gl of 10% SDS. An aliquot (1 ,ul)
of 250 mm EDTA and 2 ,ul of a 0.8 mg ml-' solution ofproteinase
K was added, and samples were incubated at 37°C for 30 min to
digest the Topo II. Final products were mixed with 2.5,l of
loading buffer (60% sucrose, 0.05% bromophenol blue, 0.05%
xylene cyanole FF, and 10 mM Tris-HCI, pH 7.9), heated at 70°C
for 1 min, and subjected to electrophoresis in 1% agarose (MCB)
gels in 40 mm Tris-acetate and 2 mm EDTA at 4 V cm-'. After
electrophoresis; DNA bands were stained with ethidium bromide
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Figure 3 NK109-induced cleavage activity of purified DNA Topo II.
Reaction mixtures (20gl each) containing purified DNA Topo II and pBR322
DNA and NK109 or etoposide at concentrations of 25 and 50 or 12.5 and
25 9g ml-1, respectively, were incubated at 370C for 10 min, and then were
terminated by addition of 4 ,ul of 5% SDS and proteinase K at 2 mg ml-'
(SDS/PK). Proteinase K digestion was performed at 370C for 30 min.
Reaction mixtures were then analysed by 1.0% agarose gel electrophoresis.
The resulting bands were identified as relaxed, linear and supercoiled forms
of various topological isomers of pBR322 DNA
and visualized by transillumination with ultraviolet light (300 nm).
The bands were photographed through Kodak 24A and 12 filters
using Polaroid type 665 positive-negative film.
Drug accumulation study
The accumulation of [3H]NK109 in the cells was determined by a
previously described method (Kanzawa etal, 1990, 1995). Foreval-
uation of drug accumulation, exponentially growing cells were
harvested, 2 x 107 cells in 0.98 ml ofculture medium were preincu-
bated at 37°C in a water bath for 45 min and the cells were then
exposed to 75 gM [3H]NK109 at 37'C in a humidified incubator
with 5% carbon dioxide. After various incubation times, the cells
were collected by low-speed centrifugation, washed once with ice-
cold PBS and centrifuged. The resulting cell pellet was dissolved in
0.5 ml of 90% formic acid. Clear-sol TM 1 solution (3 ml; Nacalai
Tesque, Kyoto, Japan) was added to each tube and the radioactivity
was measured using a liquid scintillation counter (LS6000TA,
Beckman Instruments, Irvine, CA, USA). For the efflux study, cells
were incubated with RPMI-FBS containing 75 jiM [3H]NK109 at
37°C for60 min before being washedtwice with drug-free medium.
The subsequent process was then carried out as described above.
Detection of P-glycoprotein expression by flow
cytometry
For flow cytometric analysis (Nishio et al, 1990), exponentially
growing AdrR MCF7 and K562/ADM cells (106) were washed
with PBS and incubated for 30 min with 50jil ofanti-human P-gp
monoclonal antibody (MRK-16, 10 ng ml-') at 4°C and used as
isotype controls. The cells were washed three times with cold PBS
and incubated for a further 30 min with 50 jl of fluorescein
isothiocyanate (FITC) at 4°C. The fluorescence intensity of each
cell line preparation was measured by flow cytometry (Hewlett
Packard model 9000-340 computer interfaced with FACScan).
Analysis of cell-surface glycoproteins
Membrane vesicles were separated by the method ofIshikawa and
Ali-Osman (1993). Membrane vesicles were incubated with
0.75 jM [3H]azidopine (53 Ci mmol-') for 15 min at room temper-
ature in the presence or absence ofvarious drugs. Aftercontinuous
irradiation at 366 nm for 20 min at 25'C, samples were solubilized
in an SDS sample buffer and run on a 7.5% SDS-polyacrylamide
gel containing 4.5 M urea at a constant current of 20 mA for about
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Figure 4 Anti-tumour effects of NK109, doxorubicin, cisplatin and etoposide on the growth of several human cancer cell lines and their corresponding drug-
resistant cells. The anti-tumour activity was measured using the regrowth assay, described in Materials and methods. Exponentially growing cells (2 x 104 cells
ml-') were incubated in medium containing the drug at the indicated concentration at 370C for 7 days, after which the cells were counted and cell growth ratios
were calculated. A, B and C show concentration-response curves of NK109 and doxorubicin against parental cells (0) and resistant cells (0) of the K562,
MCF7 and SBC-3 cell lines respectively. D and E show concentration-response curves of NK109 and cisplatin against parental cells (0) and resistant cells (0)
of the PC-9 and PC-14 cell lines respectively. F and G show concentration-response curves of NK109 and etoposide against parental cells (0) and resistant
cells (0) of the SKOV3 and H69 cell lines respectively
4 h (Bruggemann et al, 1989). The gels were placed in Amplify
(Amersham) for 30 min, dried and subjected to autoradiography at
-70°C using Kodak XAR film.
In vivo anti-tumour effect assay
Female SCID mice (5 weeks old, weighing approximately 20 g)
were purchased from Nihon Clea (Tokyo, Japan) and were main-
tained in a room with a constant temperature (24 ± 1°C) and relative
humidity (70 ± 2%), with 12 h oflight a day, and were fed an X-ray
irradiated commercial diet (CMF; Oriental Yeast, Tokyo, Japan)
and sterilized water ad libitum, in accordance with the guidelines
of our institute (Kondo et al 1994). All animals were inoculated
with exponentially growing tumourcells (3 x 10 cells per0.05 mI)
of the PC-14/P or PC-14/CDDP cell lines, which were injected
subcutaneously into the right flank using an 18 G needle. When the
tumour volumes increased to 500-1000mm3, 15-20 days after
inoculation, the mice were divided randomly into several groups
(six mice per group), in which the average tumour volumes were
almost equal.
NK109 at various doses (100, 125, and 150 mg kg-') dissolved
in physiological saline was injected intraperitoneally (i.p.) on days
0, 4 and 8. Cisplatin at 4 mg kg-' was injected as positive control in
order to evaluate the degree of resistance to cisplatin in PC-
14/CDDP cells. After drug treatment, survivors were ascertained
every day during the experiment and the anti-tumour activity was
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Figure 5 Uptake of NK109 by K562/P and K562/ADM cells. Exponentially
growing cells (2 x 107 cells pertest) were preincubated at 370C for 45 min
and then incubated with [3H]NK109 at 370C for the indicated time, after which
the cells were collected, washed with PBS, and dissolved in formic acid.
Then the radioactivity was measured with a liquid scintillation counter. 0 and
O show uptake of NK109 by K562/P and K562/ADM cells respectively. Efflux
of NK109 was determined from the decline in the NK109 content of cells,
accumulated during the [3H]NK1 09 incubation, in drug-free medium for the
indicated times. 0 and * show efflux of NK109 from K562/P and K562/ADM
cells respectively
evaluated by the increase in lifespan (ILS), which was calculated
by subtracting from 100 the percentage of the ratio of the mean
survival times oftreated vs untreated groups.
RESULTS
Catalytic activity of DNA Topo 11
First, we confirmed the inhibiting effect of NK109 on DNA Topo
II catalytic activity that was reported to be the mechanism ofcyto-
toxicity of NK109 (Kabasawa et al, 1996). Catalytic activity of
Topo II was assayed by relaxation of supercoiled pBR322 DNA
and the result is shown in Figure 2. In the absence of Topo II,
pBR322 DNA migrates predominantly in the fast moving super-
coiled state. Addition ofTopo II without drug results in conversion
of the supercoiled form into the relaxed DNA configurations.
NK109 inhibited the ability ofTopo II to relax supercoiled DNA at
5 jig ml-' However, at concentrations of less than 20jg ml-',
NK109 did not inhibit the relaxation. As a reference compound,
etoposide also inhibited the relaxation ofpBR322 DNA by Topo II
at the same concentration as shown in Figure 2. NK109 inhibits
the catalytic activities of purified DNA Topo II in vitro, and its
efficacy is as high as etoposide.
Effect of NK109 on the DNA cleavage of topo 11
The effect ofNK109 on the DNA cleavage ofTopo II was studied
by 25-50 jg ml-' drug in reaction mixtures (Figure 3). Topo II-
mediated DNA strand passage requires breaking and rejoining of
the double-stranded DNA. During this process, the enzyme
becomes covalently linked to the 5'-phosphate of both DNA
strands via a tyrosine-DNA phosphodiester of both DNA strands
via a tyrosine-DNA phosphodiester linkage (Tse et al, 1980). The
covalent reaction intermediate is called the cleavable complex and
can be demonstrated experimentally by the enzyme-dependent
formation of linear DNA from supercoiled DNA after treatment
with SDS and proteinase K (Liu et al, 1983). Clinically used DNA
topoisomerase II inhibitors such as doxorubicin and etoposide act
by stabilizing the cleavable complex (Nelson et al, 1984; Ross et
al, 1984; Tewey et al, 1984). NK109 at concentrations up to
10 jig ml-' did not induce DNA cleavage (data not shown). In
contrast, 25 jg ml-l NK109 completely inhibited the cleavable
complex formation as shown in Figure 3. A similar effect was also
observed in the treatment using etoposide. These results suggest
that DNA Topo II is a target ofNK109 action and this action may
play a role in the cytotoxicity ofNK109.
In vitro growth-inhibiting activity of NK109 in drug-
resistant cells
We examined whether NK109 showed cytotoxicity against a panel
of multidrug-resistant cell lines, such as K562/ADM, AdrR
MCF7, SBC-3/ADM and H69/VP. The sensitivity or resistance
was verified by regrowth assays in a continuous drug exposure
system. Resistance indices were determined by comparing the
toxic doses allowing 50% survival (IC50) ofresistant cell lines with
their parent cell lines. Resistance indices of K562/ADM, AdrR
MCF7 and SBC-3/ADM were 59.8-, 62.0- and 10.2-fold as shown
in Figure 4A-C respectively. The cytotoxicity of NK109 against
these three doxorubicin-resistant cell lines was determined. The
IC5, of NK109 for K562/ADM cells was 0.045 jg ml-', which is
almost the same as that (0.041 jg ml-') of the parent cell line,
suggesting no cross-resistance to NK109, as shown in Figure 4A.
The IC5, ofNK109 for AdrR MCF7 cells was 0.42 jg ml-' which
is 2.1 times that (0.20 jg ml-') ofthe parent cell line (Figure 4B).
SBC-3/ADM cells were almost as sensitive to NK109 as SBC-3/P
cells (Figure 4C). The etoposide-resistant H69/VP cell line, having
a typical P-gp-mediated MDR phenotype, also showed no cross-
resistance to NK109 (Figure 4G).
Cisplatin-resistant PC-9/CDDP and PC-14/CDDP human non-
small-cell lung cancer cells were examined for cross-resistance to
NK109. The resistance ratios of PC-9/CDDP cells and PC-
14/CDDP cells for cisplatin were 4.4- and 12.9-fold respectively.
The cytotoxicities of NK109 against these cisplatin-resistant cell
lines were estimated. The IC50 of NK109 for PC-9/CDDP cells
was 0.19 jig ml-', which is almost the same as for the parental cell
line (0.17 jig ml-') (Figure 4D). PC-14/CDDP cells showed no
cross-resistance to NK109 as shown in Figure 4E. Thus, NK109
was effective against cisplatin-resistant PC-9 and PC-14 cells as
well as against their parental cells.
We postulated that NK109 would not inhibit the growth of
etoposide-resistant cells because NK109 is thought to exert its
cytotoxicity by the formation of cleavable Topo II complexes, as
does etoposide. SKOV3/VP cells are 9.6-fold resistant to etopo-
side and decreased Topo II activity is the resistance mechanism
(Kubota et al, 1994). the IC5, of NK109 for the growth of
SKOV3/VP cells was 0.21 jig ml-', which is little higher than that
ofthe parental cells (Figure 4F). Thus, contrary to expectation, we
did not observe cross-resistance ofSKOV3/VP cells to NK109.
Intracellular accumulation of NK109 in drug-resistant
cells
We studied reactions ofNK109 with several molecular and biolog-
ical alterations associated with resistance. First, the time course of
NK109 uptake by K562 cells was determined, because resistance
to anti-tumour drugs is frequently characterized by diminished
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Figure 6 P-glycoprotein expression in K562/ADM and AdrR MCF7 cell lines. In each overlay histogram, the horizontal axis records fluorescein isothiocyanate
fluorescence of MRK-1 6-treated or isotype control cells and the vertical axis represents the number of cells. Histograms in black and those in white are of MRK-
16-treated cells and the isotype controls respectively. Numbers of P-glycoprotein-positive cells, after subtraction of fluorescent cells from the isotype control, are
recorded as a percentage. (A) K562/ADM; (B) AdrR MCF7
drug accumulation in resistant cells. When the cells were incu-
bated with 75 l.tM VH]NK109 (0.5 pCi), the cellular uptake of
NK109 into K562/ADM cells was the same as that in the parental
cells. Further, we determined the efflux of NK109 from the resis-
tant cells compared with the parent cells and the results are shown
(0 and * for K562/P and K562/ADM respectively) in Figure 5.
Efflux did not differ between the cell lines, as shown in Figure 5.
The mechanism of resistance of the cisplatin-resistant PC-
14/CDDP cell line is thought to be impaired drug uptake, so we
determined the cellular uptake of NK109 by PC14/P and
PC 14/CDDP cells. No difference in the uptake of NK 109 between
these cell lines was observed (data not shown).
Detection of P-gp in doxorubicin-resistant cells
The K562/ADM and AdrR MCF7 cells were confirmed to be P-gp
positive. Flow cytometric overlay histograms of isotype controls
and MRK-16 antibody-treated cells are shown in Figure 6. In the
parental cell lines K562 and MCF7, less than 1% of cells stained
positive with the P-gp-specific MRK- 16 monoclonal antibody
(data not shown). In contrast, both K562/ADM and AdrR MCF7
cells reacted strongly with MRK-16 (Figure 6A and 6B). SBC-
3/ADM and H69/VP cells also exhibited P-gp (data not shown).
Binding activity of NK109 with P-gp
P-gp is a plasma membrane protein that confers MDR by actively
transporting the cytotoxic drugs out of the cells. Therefore, we
exanmined the affinity of NK109 for P-gp. Azidopine is a
photoaffinity analogue of the dihydropyridine class of calcium
channel blockers that specifically labels P-gp (Yang et al, 1988).
Verapamil, a calcium channel blocker, inhibited this labelling, as
shown in Figure 7. Doxorubicin also inhibited photolabelling of
P-gp by L3H] azidopine. This result suggests that both verapamil
and doxorubicin are substrates for active transport in plasma
membrane vesicles prepared from multidrug-resistant K562 cells.
In contrast, NK109 does not block photolabelling when present at
up to a 100-fold molar excess (Figure 7), suggesting that NK109 is
not a substrate for P-gp and, therefore, that accumulation of
NK 109 was not diminished in resistant cells.
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Topo I and Topo 11 activities of etoposide-resistant cells
The total cellular Topo II activities ofcrude nuclear extracts eluted
with 0.35 M sodium chloride from SKOV3/P cells and their etopo-
side-resistant sublines were measured. The decatenation ofkDNA
incubated with different amounts of SKOV3/P and SKOV3/VP
nuclear protein extracts is shown in Figure 8B. Decatenated forms
were not observed for SKOV3/VP even when 0.03 ,ug of nuclear
extract was used, indicating that Topo II activity of SKOV3/VP
cells was reduced to about one-tenth of that of the parent cells. In
contrast, the Topo I activity of SKOV3/VP extracts was not
changed compared with the parent cells (Figure 8A). These results
indicate that the resistance of SKOV3/VP cells to etoposide is due
to reduced Topo II activity. Non-cross-resistance of etoposide-
resistant SKOV3IVP cells to NK109 suggests that the mechanism
ofaction ofNK109 differs from that ofetoposide.
In vivo anti-tumour activity of NK109 against drug-
resistant cells
In order to confirm the in vitro results of non-cross-resistance to
NK109 in drug-resistant cells, we checked the transplantability of
several human carcinoma cell lines in nude or SCID mice. We
found that both PC-14/P and PC-14/CDDP were transplantable in
SCID mice, producing high take rates, and thus SCID mice were
used in this experiment.
Figure 9B shows the mean ILS of cisplatin-treated SCID mice
with PC-14/P and PC-14/CDDP cell xenografts. The cisplatin
treatment suppressed tumour growth only in the PC-14/P cell line
and not in the resistant subline PC-14/CDDP. Therefore, the ILSs
for cisplatin (4 mg kg-') for PC-14/P and PC-14/CDDP cells were
44% and 2% respectively. In contrast, the ILSs for NK109 at 100,
125, and 150 mg kg-' for PC-14/P cells were 8%, 26% and 33%
respectively. The ILSs for PC-14/CDDP cells were 18%, 25% and
27% respectively as shown in Figure 9A. These data indicate that
cisplatin-resistant cells are not cross-resistant to NK109 in vivo, as
well as in vitro.
DISCUSSION
Fagaridine isolated from the root bark of Fagara xanthoxyloides
was reported to inhibit the growth of certain human leukaemias
and several murine tumour cells, and 2,3-(methylenedioxy)-
5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium was
determined as its chemical structure, which is similar to that of
NK109 (Torto and Mensah, 1973; Hanaoka et al, 1985). However,
Kessar et al (1988) indicated an incorrect structure for fagaridine
and revised a different placement (at the C-8 position on ring A of
benzo[c]phenanthridine) of the hydroxy group. Therefore, the
NK109 tested in this study is a different positional isomer from
fagaridine and a novel anti-tumour agent.
Its cytotoxic mechanism was confirmed to be due to Topo II
inhibition. The topoisomerases are nuclear enzymes that catalyse
the concerted breaking and rejoining of DNA strands, thereby
controlling the topological states of DNA during many DNA
metabolic processes, including replication, recombination, tran-
scription and chromosome segregation at mitosis (Wang, 1985).
They are considered to be important therapeutic targets in cancer
chemotherapy. In addition, recent studies have shown that several
chemotherapeutic drugs, such as topoisomerase inhibitors, trigger
apoptosis (Kaufmann, 1989). We have also demonstrated that
NK109 induces single- and double-strand DNA breaks and DNA
fragmentation, which is a marker for apoptosis, in a human small-
cell lung cancer cell line. Furthermore, we showed that protein and
RNA syntheses were not required for apoptosis induced by NK109
(Fukuda et al, 1996).
In this study, we determined the efficacy of NK109 against an
etoposide-resistant ovarian carcinomacell line, SKOV3/VP, which
has reduced Topo II activity as one of the resistance mechanisms.
The resistant cells exhibited marked sensitivity to NK109
compared with their parent cells, suggesting that the cytotoxic
mechanism of NK109 differs from that of etoposide. This was
supported by the observation that NK109 induces more DNA
strand breaks, especially DNA double-strand breaks, than the
same concentration of etoposide (Fukuda et al, 1996). Wang et al
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Figure 9 Increase in lifespan (ILS) of SCID mice with PC-14/P (0) and PC-14/CDDP (0) cell xenografts, treated by injection (i.p.) of NK109 at doses of 100,
125 and 150 mg kg-' (A) and cisplatin at a dose of 4 mg kg-' (B) as a reference drug on days 0, 4 and 8. ILS was calculated as described in Materials and
methods
(1993) reported that fagaronine and nitidine being similar to
NK109 are characterized as inhibitors of Topo I function.
Therefore, we are studying the ability ofNK109 to induce single-
strand DNA breaks or act as a Topo I poison.
The development of multiple resistance to anti-tumour agents
by human tumour cells is recognized as one ofthe major obstacles
to successful cancer chemotherapy. MDR is frequently character-
ized by enhanced drug efflux because of a membrane glycoprotein
(P-gp; Mr 170 000) encoded by the MDRJ gene in human cancer
cells (Fojo et al, 1985). The kinetics ofdrug uptake, accumulation
andefflux also suggests thatmultidrug-resistant cells remove these
cytotoxic drugs from the cell by active transport across the plasma
British JoumalofCancer(1997) 76(5), 571-581
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membrane (Skovsgaard, 1978). Overexpression ofP-gp is widely
observed in various multidrug-resistant cell lines (Dano, 1973).
Further, multidrug-resistant cells selected for resistance to one
drug become simultaneously resistant to many other drugs that are
structurally and functionally unrelated to the selected drug
(Gottesman and Pastan, 1988). For instance, human KB carcinoma
cells selected for resistance to colchicine are also resistant to
vinblastine, vincristine, actinomycin D, daunomycin and doxo-
rubicin, but they are not resistant to methotrexate, cytosine arabi-
noside and dexamethasone (Fojo et al, 1985).
Some calcium channel blockers, such as verapamil, diltiazem,
and dihydropyridine analogues, are reported to reverse the MDR
phenotype (Safa et al, 1987; Akiyama et al, 1988). However, no
agent that reverses multidrug resistance can be clinically used in
full doses to reverse resistance. Thus, the development of NK109
as a novel anti-tumour drug that is not a substrate for calcium
channel blockers of P-gp will be potentially valuable. Moreover,
the efficacy ofNK109 is not susceptible to several molecular alter-
ations associated with drug resistance. The clinical study of this
compound is now in progress in Japan. The drug is clearly very
active against resistant solid tumour cell lines, but its clinical toxi-
city needs elucidation before human clinical efficacy trials.
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ABBREVIATIONS
Topo I, DNA topoisomerase I; topo II, DNA topoisomerase II;
kDNA, kinetoplast DNA; PBS, phosphate-buffered saline; PMSF,
phenylmethylsulphonyl fluoride; SDS, sodium dodecyl sulphate;
NB, nuclear buffer.
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